-
Hefei high-tech zone home to 82 high-growth enterprises
2021-04-22
The science and technology bureau of Hefei recently released a list of 165 high-growth enterprises in the city, 82 of which are located in the Hefei National High-Tech Industry Development Zone in Hefei, capital of East China's Anhui province.
-
Hefei smart speech industrial cluster wins national honor
2021-04-14
Hefei's smart speech industrial cluster created by China Speech Valley was recently named on the Advanced Manufacturing Industrial Cluster Final Winners List released by the Ministry of Industry and Information Technology.
-
Hefei Advanced Computing Center to open in June
2021-04-14
Located in Hefei National High-tech Industry Development Zone, Hefei Advanced Computing Center is expected to open to provide services in June this year, its operator says.
-
Quantum computing chip laboratory set for Hefei high-tech zone
2021-04-08
Hefei-based Origin Quantum and Nexchip Semiconductor Corporation signed an agreement to establish a joint quantum computing chip laboratory in the Hefei National High-tech Industry Development Zone on April 2.
-
Hefei IC company CFMEE listed on STAR market
2021-04-08
Hefei-based company CFMEE was listed on the Nasdaq-like STAR Market of the Shanghai Stock Exchange on April 1.
-
Anhui Overseas Students Pioneer Park set up in Hefei high-tech zone
2021-04-02
The Anhui Overseas Students Pioneering Park was set up in the Hefei National High-Tech Industry Development Zone in Anhui province on March 25.
-
German delegation visits Sino-German Innovation Center
2021-04-02
A delegation led by Thomas Triller, deputy consul general of Germany in Shanghai, visited the Sino-German Innovation Center at Hefei National High-Tech Industry Development Zone in Hefei, Anhui province, on March 29.
-
Trials show Chinese COVID-19 protein subunit vaccine safe, effective
2021-03-29
A China-developed recombinant protein subunit vaccine against COVID-19, which has been approved for emergency use, has shown to be safe and can elicit an antibody response in early-stage trials, according to a study published this week in The Lancet Infectious Diseases journal.





